Objective: To compare neurodevelopmental outcomes using Bayley Scales of Infant Development (BSID), between encephalopathic neonates undergoing therapeutic hypothermia (TH), sedated with either continuous dexmedetomidine or intermittent morphine.

Study Design: Retrospective, observational cohort study including encephalopathic neonates born between 2014 - 2022 that underwent TH at two Regional Perinatal Centres, and completed neurodevelopmental follow-up assessments.

Results: There were no significant differences in demographics or short-term neurologic outcomes between morphine (n = 30) and dexmedetomidine (n = 32) groups. At 12 months, median motor composite scores (104 vs 98.5, p = 0.02) and median fine motor scaled scores (SS) (11 vs 10, p = 0.01) were significantly higher in the dexmedetomidine group. Median expressive language SS were slightly higher in the morphine group (11 v 10, p = 0.05). BSID scores at 18-24 months were similar.

Conclusion: This study supports the use of dexmedetomidine as first-line sedation agent during TH, given comparable 18-24 month neurodevelopmental outcomes.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41372-025-02227-yDOI Listing

Publication Analysis

Top Keywords

neurodevelopmental outcomes
12
encephalopathic neonates
12
neonates undergoing
8
undergoing therapeutic
8
therapeutic hypothermia
8
dexmedetomidine
5
dexmedetomidine versus
4
versus morphine
4
morphine sedation
4
sedation long-term
4

Similar Publications

Maternal Obesity and Neurodevelopment of the Offspring.

Nutrients

March 2025

Unit of Developmental and Behavioral Paediatrics, First Department of Paediatrics, Agia Sophia Children's Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Background: An increasing amount of evidence, derived from both human epidemiological studies and animal research, suggests that exposure to maternal obesity in utero is linked to adverse neurodevelopmental outcomes in the offspring. These can include attention deficit hyperactivity disorder, autism spectrum disorders, intellectual disability, and cerebral palsy.

Methods: A thorough search in Medline/PubMed and Google Scholar databases was performed by two independent reviewers in order to investigate the link between the exposure to maternal obesity and neurodevelopmental outcomes in the offspring.

View Article and Find Full Text PDF

Background: Most pregnant women have choline intakes below recommendations. Animal studies suggest that choline supplementation during pregnancy improves cognitive outcomes in the offspring. This review aims to determine whether higher choline levels during pregnancy are associated with improved child brain development.

View Article and Find Full Text PDF

Preventing neurodevelopmental impairment after extremely preterm birth remains challenging. While breast milk feeding is linked to better neurodevelopment, the underlying mechanisms are unclear. This study explored the association between individual human milk oligosaccharides (HMO) and neurodevelopment at two years of age in extremely preterm children.

View Article and Find Full Text PDF

: Iodine is essential for thyroid hormone (TH) synthesis, and THs in pregnant women are critical for fetal brain development. It is unclear whether urinary iodine concentrations (UICs) are associated with thyroid parameters in pregnant women and neurodevelopment in their 3-4-year-old children. : In the Canadian Maternal-Infant Research on Environmental Chemicals (MIREC) cohort, we categorized UIC adjusted for urinary creatinine (UIC/Cr) in the first two trimesters as <150, 150-500, or ≥500 µg/g.

View Article and Find Full Text PDF

MicroRNA Profiling Identifies Age-Associated MicroRNAs and Potential Biomarkers for Early Diagnosis of Autism.

Int J Mol Sci

February 2025

Neurological Disorders Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, Doha P.O. Box 34110, Qatar.

Autism spectrum disorder (ASD) is a neurodevelopmental disorder in which early diagnosis is critical for effective intervention and improved outcomes. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and have emerged as promising biomarkers for neurological disorders, including ASD. In our previous discovery study, we identified dysregulated expression of several miRNAs in the plasma samples of children with ASD aged 5-12 years.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!